Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Virtual reality is seeing an upsurge in use by mental health practitioners for treating conditions such as post-traumatic stress disorder, panic disorders and anxiety in a safe and controlled manner. With the advent of affordable VR headsets and technological advances, companies and researchers worldwide are seizing on the opportunity to bring such techniques as VR exposure therapy and cognitive behavioral therapy to telemedicine, specialty clinics and directly to consumers to improve outcomes and better lives.
Latest From Market Intelligence
On this week's Medtech Insight podcast: US FDA Commissioner Scott Gottlieb defends his agency’s budget; AdvaMed’s new chair talks to Medtech Insight about challenges he faces and where he’s leading the industry group; a close look at mobile technology company Qualcomm Life; a two-part Medtech Insight series on pain management is highlighted.
In the global pain management market, spinal cord stimulation (SCS) systems are expected to continue to be the fastest-growing segment with increasing competition among device manufacturers to develop innovative, targeted therapies. In this second article of a two-part series, we'll discuss the competitive landscape in the SCS market, the key players, emerging companies and their respective technologies.
The field of neuromodulation for treating chronic pain is growing rapidly, especially in the fastest-growing spinal cord stimulation (SCS) market segment, which is expected to hit $2.4bn by 2021. This article, the first of a two-part series, will explore what the key drivers and limitations are for the SCS market and provide insight from three established pain management specialists on what factors will push wider adoption of this therapy.
On this week's Medtech Insight podcast: Scott Gottlieb takes the reins at FDA; US agency ready to accept 510(k) devices into the Expedited Access Pathway; plans finally revealed for “program alignment,” which will change FDA’s approach to facility inspections; news from the BioTrinity 2017 conference; a look at the landscape of the soft tissue fixation device market.
Global sales for arthroscopy and sports medicine devices are predicted to hit $6.5bn by 2021. This will be driven by the fast-growing soft tissue fixation products segment: significant changes in market dynamics are expected over the next few years, as hip fixation procedures pick up pace. This article delves into the landscape of the soft tissue fixation device market, as well as the four key segments in the arthroscopy devices space. It will also analyze the key players in these markets, highlight trends and discuss the biggest challenges.
The global diabetes management devices market is expected to exceed $11.2bn by 2020, driven largely by the rising diabetes epidemic. This, in turn, is fueling significant innovation such as next-generation, automated artificial pancreas systems and miniaturized, less-invasive wireless technologies that can continuously track and analyze glucose levels in real-time. This feature looks more closely at these and other potentially groundbreaking new technologies, as well as the competitive landscape of the two major product segments – insulin pumps and blood glucose monitors.
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.